GlobeNewswire

Cornell receives $35M to support cassava development for smallholder farmers in sub-Saharan Africa

Share

Ithaca, New York, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Cassava is vital to the food security of millions of Africans who eat some form of the root crop daily. Although cassava breeders are making progress, they still face significant challenges in developing disease-resistant varieties that also increase overall yield and respond to the needs of smallholder farmers and processors. Cornell University will expand international efforts to deliver improved varieties of cassava to smallholder farmers in sub-Saharan Africa with $35 million in new funding from the Bill & Melinda Gates Foundation and UK aid from the United Kingdom.

"This grant funds a second five-year phase that will allow us to build on previous work and focus on getting improved varieties into farmers' fields," said Ronnie Coffman, international plant breeder and director of Cornell's International Programs in the College of Agriculture and Life Sciences, who leads the project. 

During Phase 1 of the Next Generation Cassava Breeding project - also funded by the Gates Foundation and UK aid from 2012 to 2017 - researchers shortened the breeding cycle for new cassava varieties by improving flowering and using genomic selection. Through analyzing plant genotypes and identifying cassava lines with desirable traits, such as resistance to cassava brown streak disease or high dry matter content, breeders also improved their ability to make selections based on genetics and probability without having to wait for seedlings to reach adulthood. These methods save breeding time for a crop where flowering and sexual propagation are issues.

Another goal of Phase 1 was to make cassava genomic information publicly accessible on an open database. Cassava researchers all over the world are now comparing results and improving breeding programs without duplicating efforts by using Cassavabase. To reduce cost per progeny and improve the quality of data uploaded to Cassavabase in Phase 2, NextGen researchers will use additional methods of whole genome sequencing. 

"Our focus for the next five years will be to translate this research into breeding practices to increase impact," said Chiedozie Egesi, NextGen project director and adjunct professor of plant breeding and genetics at Cornell, who is based at the International Institute of Tropical Agriculture (IITA) in Nigeria. "A key goal in Phase 2 will be to identify traits preferred by farmers and end-users and incorporate them into new cassava lines to ensure that varieties are responsive to people's needs."

Egesi said, "We believe we will accelerate genetic gain as well as adopted genetic gain, increase the yields and resilience of cassava production by smallholder farmers, and move African cassava breeding toward greater capacity."

"Among the 30 new clones developed at IITA using our methods, 10 had higher dry matter yield than any clone currently available for smallholder farmers in Nigeria," said Jean-Luc Jannink, a research plant geneticist with the United States Department of Agriculture, Agricultural Research Service  (USDA-ARS) and Cornell adjunct associate professor in the Department of Plant Breeding and Genetics at Cornell. "Dry matter yield is a close proxy to food yield. Conservatively, we believe that we will increase the rate of genetic gain in cassava by 30 to 50 percent." 

Said Peter Kulakow, IITA cassava breeder and geneticist: "Genetic gain is a measure of the improvement of plant performance between generations and a goal of most modern breeding programs. Swifter improvements mean more new varieties can be tested and released." 

At the sixth annual Next Gen Cassava meeting, Feb. 19-24 in Dar es Salaam, Tanzania, teams of NextGen breeders, geneticists, data analysts, computer programmers, food technologists, social scientists and crop protectionists will be focusing on goals for Phase 2 and discussing how to better coordinate and leverage the exchange of germplasm and genotypic and phenotypic data from each other.

Developing capacity for sustainable breeding programs

Compared with other major staples like maize, rice and wheat, cassava has undergone few advances in productivity and yield over the last 50 years, making it an ideal candidate for breeding improvement. Because cassava is clonally propagated and has a low multiplication rate, it can take almost six to eight years before a new cassava variety makes it from breeders' nurseries through field trials to farmers' fields. Most breeding efforts focus on product development  - goals set by scientists and researchers without accounting for the preferences of farmers. In practice, this can result in poor adoption of new varieties and unrealized potential. 

"Breeders must be able to more quickly develop cassava varieties that resist diseases, are climate resilient and meet the needs of end-users and consumers," said Egesi.

Strengthening the capacity of national breeding programs will be critical in achieving self-sustaining breeding systems in sub-Saharan Africa. Over the next five years, NextGen researchers will continue to train the next generation of sub-Sahara African cassava breeders in modern plant breeding techniques like genomic selection and improved breeding methods.

International and regional partnerships are another important element of sustainability. NextGen researchers are reaching out to their counterparts in Ghana, Rwanda, Mozambique, Sierra Leone and the Democratic Republic of Congo to create a broader network of researchers who can work together to improve livelihoods and food security.

In Africa, NextGen collaborators include the International Institute of Tropical Agriculture, the National Root Crops Research Institute and West Africa Centre for Crop Improvement in Nigeria; the National Crops Resources Research Institute and Makerere University in Uganda; and the Tanzania Agricultural Research Institute in Tanzania. In South America, collaborators include Embrapa in Brazil and the International Center for Tropical Agriculture in Colombia. In the US, collaborators are Cornell University (who leads the project), the Boyce Thompson Institute at Cornell, the University of Hawaii, and the USDA-ARS in Ithaca.

For more information see www.nextgencassava.org   

 

 

# # #

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/d1896398-975a-4943-85b0-4f4b165f5678

Attachments:

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/4e3e5f6e-d4b9-45d1-b74d-8248eb7bb1ba

Linda McCandless
Cornell University 
6072275920
llm3@cornell.edu



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cornell University via Globenewswire

About GlobeNewswire

GlobeNewswire



Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Karolinska Development delays publication of its Annual Report for 2018 and changes date for the Annual General Meeting26.4.2019 08:00:00 CESTPress release

STOCKHOLM, SWEDEN - 26 April 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that The Board of Directors has decided to delay the publication of its Annual Report for 2018. Karolinska Development has changed the date for the Annual General Meeting to June 26, 2019. The date for publication of the Annual Report for 2018 has been changed from April 26 to April 30, 2019. Karolinska Development has changed the date for the Annual General Meeting from June 4 to June 26, 2019. Notice to the Annual General Meeting will be published in a separate press release. For more information, please contact: Viktor Drvota, CEO, Karolinska Development AB Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, CFO, Karolinska Development AB Phone: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TO THE EDITORS About Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investmen

Karolinska Development senarelägger publicering av årsredovisningen för 2018 och meddelar nytt datum för årsstämma26.4.2019 08:00:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 26 april 2019. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att styrelsen har beslutat att senarelägga publiceringen av årsredovisningen för 2018. Karolinska Development har ändrat datum för årsstämman till den 26 juni 2019. Publiceringen av årsredovisningen för 2018 flyttas från den 26 april till den 30 april 2019. Karolinska Development har ändrat datum för årsstämman från den 4 juni till den 26 juni 2019. Kallelse till årsstämman kommer att publiceras senare i ett separat pressmeddelande. För ytterligare information, vänligen kontakta: Viktor Drvota, vd, Karolinska Development AB Tel: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com Fredrik Järrsten, finanschef, Karolinska Development AB Tel: +46 70 496 46 28, e-mail: fredrik.jarrsten@karolinskadevelopment.com TILL REDAKTÖRERNA Om Karolinska Development AB Karolinska Development AB (Nasdaq Stockholm: KDEV) är ett nordiskt investmentbolag inom life science. Bolaget fokuserar p

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPress release

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPress release

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom